1. Home
  2. KLRS vs LFVN Comparison

KLRS vs LFVN Comparison

Compare KLRS & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kalaris Therapeutics Inc.

KLRS

Kalaris Therapeutics Inc.

HOLD

Current Price

$3.90

Market Cap

92.8M

Sector

Health Care

ML Signal

HOLD

Logo Lifevantage Corporation (Delaware)

LFVN

Lifevantage Corporation (Delaware)

HOLD

Current Price

$6.25

Market Cap

78.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KLRS
LFVN
Founded
2019
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
92.8M
78.0M
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
KLRS
LFVN
Price
$3.90
$6.25
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$19.00
$11.00
AVG Volume (30 Days)
43.5K
48.4K
Earning Date
05-13-2026
05-06-2026
Dividend Yield
N/A
3.56%
EPS Growth
75.70
N/A
EPS
N/A
0.40
Revenue
$165,000.00
$203,204,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$15.50
Revenue Growth
N/A
1.86
52 Week Low
$3.03
$3.90
52 Week High
$11.88
$12.10

Technical Indicators

Market Signals
Indicator
KLRS
LFVN
Relative Strength Index (RSI) 47.07 40.47
Support Level $3.92 $6.17
Resistance Level $4.37 $6.97
Average True Range (ATR) 0.24 0.32
MACD -0.01 -0.06
Stochastic Oscillator 30.00 32.70

Price Performance

Historical Comparison
KLRS
LFVN

About KLRS Kalaris Therapeutics Inc.

Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.

About LFVN Lifevantage Corporation (Delaware)

Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of in the United States, Mexico, Canada, Japan, Taiwan, Thailand, Australia, New Zealand, the United Kingdom, the Netherlands, Germany, Austria, Spain, Ireland, Belgium, and Others. The company operates in a single operating segment by selling products directly to customers through an international network of independent consultants that operate in an integrated manner.

Share on Social Networks: